The seven areas below are not separate services. In a complex program, a design decision is a regulatory decision, a clinical endpoint is a reimbursement argument, and a manufacturing choice is a financing constraint. TEPKOS works at the level where those dependencies are resolved.
TEPKOS draws on two decades in medical technology. It takes on engagements that call for unconventional solutions to complex problems: first-of-kind technologies, unresolved regulatory territory, and programs whose difficulty lies in how their parts interact.
The decisive questions are usually clinical: whether the need is real and durable, whether the evidence can be generated at acceptable cost and time, and whether the physicians who shape practice will adopt what results.
At the strategic level, development is a question of what to build, in what order, and what the technology must prove before the next increment of capital is committed.
Novel technologies rarely fit existing market definitions. Strategy begins with the market a technology creates, and often with the company built to hold it.
Regulatory strategy matters most where precedent is thin. The choice of pathway carries consequences for evidence, timeline, labeling, and ultimately value.
Early manufacturing decisions fix cost, quality, and scalability for the life of a product. They belong in the strategy from the outset.
Clearance does not confer adoption. Adoption turns on reimbursement, clinical workflow, and the economics of every party between the device and the patient.
Capital is most efficient when each raise is matched to the risk it retires. Financing strategy follows from the technical, clinical, and regulatory plan, and shapes it in return.